Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
patisiran
Biotech
FDA delays decision on inotersen, handing lead to Alnylam
Akcea suffered the setback after the FDA asked for more time to review its response to requests for information on the rare disease antisense drug.
Nick Paul Taylor
May 4, 2018 8:28am
Alnylam builds out case for patisiran, showing drop in mortality
Apr 24, 2018 7:48am
Alnylam retools Sanofi deal to take full control of patisiran
Jan 8, 2018 6:52am
Alnylam halts fitusiran trials after patient with hemophilia dies
Sep 7, 2017 11:00am